Bolt Biotherapeutics Q2 loss $23.1M; cash $223.6M extends runway to 2025

Bolt Biotherapeutics, Inc.

2023-Q2 EPS reported -$1.25 revenue$2,206,000

Collaboration revenue $1.4M vs $0 in Q2 2021; R&D spend $18.9M, G&A $5.5M.
Cash and securities $223.6M as of June 30, extended cash runway through 2025 via portfolio prioritization.
BDC-1001 monotherapy/combination dose-escalation data and RP2D expected H2 2022.
BDC-2034 discontinued due to off-target toxicity; focus on BDC-1001, BDC-3042, and next-gen ISAC.
BDC-3042 IND-enabling studies underway; clinical start on track for 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.